Publications by authors named "Susan Low"

Claim this Profile
I
Infectious disease surveillance and management in clinical xenotransplantation: Experience with the first human porcine kidney transplant.
Jay A Fishman, Joseph El Khoury, Tatsuo Kawai, Leonardo V Riella, Nahel Elias, Susan Low

Am J Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease.
Tatsuo Kawai, Winfred W Williams, Nahel Elias, Jay A Fishman, Kerry Crisalli, Susan C Low

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and testing of a humanized porcine donor for xenotransplantation.
Ranjith P Anand, Jacob V Layer, David Heja, Takayuki Hirose, Grace Lassiter, Susan C Low

Nature· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease.
Rosemary Kanasty, Susan Low, Nupura Bhise, Jung Yang, Erick Peeke

J Control Release· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Evaluation of Thiazoloquinolinones with Linkers To Enable Targeting of CD38.
Stephen S Scully, Zachary J Minden, Ratul Mukerji, Elizaveta Andrianova, James Kaberna, Susan Low

ACS Med Chem Lett· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.
Daniel D Von Hoff, Monica M Mita, Ramesh K Ramanathan, Glen J Weiss, Alain C Mita, Lowell L Hart, Susan C Low

Clin Cancer Res· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system.
Young Ho Song, Eyoung Shin, Hong Wang, Jim Nolan, Susan Low

J Control Release· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
Susan Ashton, Young Ho Song, Jim Nolan, Elaine Cadogan, Jim Murray, Susan Low

Sci Transl Med· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway.
Sebastien Vallee, Swapnil Rakhe, Thomas Reidy, Sandra Walker, Qi Lu, Susan Low

J Interferon Cytokine Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Jeffrey Hrkach, Daniel Von Hoff, Mir Mukkaram Ali, Elizaveta Andrianova, Jason Auer, Susan Low

Sci Transl Med· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.
Jennifer A Dumont, Tongyao Liu, Susan C Low, Xin Zhang, George Kamphaus

Blood· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics in rats.
Adam R Mezo, Kevin A McDonnell, Susan C Low, Jeff Song, Tom J Reidy

Bioconjug Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PEGylation enhances the therapeutic potential of peptide antagonists of the neonatal Fc receptor, FcRn.
Adam R Mezo, Susan C Low, Todd Hoehn, Holly Palmieri

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged activity of factor IX as a monomeric Fc fusion protein.
Robert T Peters, Susan C Low, George D Kamphaus, Jennifer A Dumont, John V Amari

Blood· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of dimeric peptide antagonists of the human immunoglobulin G-human neonatal Fc receptor (IgG-FcRn) interaction.
Kevin A McDonnell, Susan C Low, Todd Hoehn, Ryan Donnelly, Holly Palmieri

J Med Chem· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of the FcRn:IgG protein-protein interaction.
Susan C Low, Adam R Mezo

AAPS J· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.
Adam R Mezo, Kevin A McDonnell, Cristina A Tan Hehir, Susan C Low, Vito J Palombella

Proc Natl Acad Sci U S A· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.
Jennifer A Dumont, Susan C Low, Robert T Peters, Alan J Bitonti

BioDrugs· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.
Alan J Bitonti, Jennifer A Dumont, Susan C Low, Robert T Peters, Keith E Kropp

Proc Natl Acad Sci U S A· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis